| 摘要 |
Tumours are sensitized to radiation by administration of 5-chlorodeoxycytidine (5-CldC) or 5-halo-2'-halo-2'-deoxycytidine or -uridine derivatives. Tetrahydrouridine (H4U) and/or 2'-deoxytetrahydrouridine (dH4U) is preferably coadministered with the deoxycytidine derivatives to inhibit deamination of the deoxycytidine derivatives. Optional pre- or concurrent treatment with agents to reduce the amount of competing metabolites to favor CldC, such as 5-fluorodeoxyuridine, results in a procedure that significantly increases the dose effects of X-radiation. Pharmaceutical composition suitable for the sensitization of tumors to radiation are also disclosed. |
